1 Department of Obstetrics and Gynaecology, 2 Department of Molecular and Cell Biology, University of Aberdeen, Aberdeen, 3 School of Animal and Microbial Sciences, University of Reading, Reading and 4 Departments of Obstetrics and Gynaecology and Physiology, St George's Hospital Medical School, London, UK
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Key words: follicle size/GnRH/GnSAF/LH/spontaneous cycle
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
We have previously demonstrated that GnSAF bioactivity is not an artefact of ovarian stimulation protocols since it is also found in spontaneous cycle follicular fluid (Fowler at al., 1995) and serum (Byrne et al., 1993). Although we know that small follicles contain much greater concentrations of GnSAF bioactivity than large follicles (Fowler et al., 1994
), the latter data were based upon follicular fluid aspirated from IVF follicles and might possibly be an artefact of the stimulation regimes and not an aspect of normal ovarian physiology. While data from unstimulated pigs and cows show that GnSAF activity is present in follicular fluid, and in pigs declined with increasing size beyond a peak of activity in follicles between 7 and 8 mm diameter (Koppenaal et al., 1992
; Kita et al., 1994
), it is important to confirm such findings in humans. For GnSAF to have a role in the timing of the LH surge, its production during the follicular phase would need to be regulated and co-ordinate with folliculogenesis.
In this paper we present evidence that in the spontaneously cycling women, GnSAF bioactivity is inversely related to follicle size, with direct implications for the role of GnSAF in the regulation of the ovarian cycle.
![]() |
Materials and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Individual follicles were microscopically dissected intact from the surrounding stroma in 14 pairs of ovaries. Patient details are shown in Table I. Follicles were dissected cleanly from adhering stromal tissue to allow for accurate assessment of diameter using callipers. The fluid was then aspirated with a fine gauge needle and centrifuged to remove cellular debris. Samples were then frozen immediately prior to use. A total of 35 follicles were collected, covering the range 325 mm. To produce adequate volumes for bioassay, hormone measurement and samples reliably representative of each size range, fluids were pooled into eight groups according to size as shown in Table II
. Follicular fluid from between two and 10 follicles was pooled to obtain each sample for follicles up to 15 mm in diameter, the number in each group falling with increased size due to the scarcity of larger follicles in ovaries collected at random stages of the menstrual cycle. As far as possible samples were pooled evenly from the range of patients so as to minimize differences between pools in terms of patient age and indication for surgery. Only two well-characterized preovulatory follicles were obtained intact during the 2 year collection period and so these were assayed as single samples due to the rarity of this fluid and consequently the novel nature of the data.
|
|
GnSAF bioassay
Adult female SpragueDawley rats (1014 weeks old) were maintained under a constant 12 h light:12 h dark, 22°C environment with access to food and water ad libitum. For each cell culture 15 rats, selected at random during the oestrous cycle, were killed by CO2 exposure followed by cervical dislocation. Dispersion and culture of the pituitary cells was carried out as described in Fowler et al. (Fowler et al., 1994) and only preparations with >75% viability of dispersed cells were used for bioassay. Primary pituitary cell cultures were at 30000 viable cells/200 µl culture medium per well in the inner 60 wells of 96-well tissue culture plates. The outer 36 wells contained 200 µl of culture medium only. The cells were cultured under sterile conditions for 24 h at 37°C in a water-saturated atmosphere of 5% CO2/95% air mixture with serum-free defined culture medium (SFDM as defined in Fowler et al. (Fowler et al., 1994
).
All experiments were then carried out on quadruplicate wells as follows: 200 µl of fresh SFDM was added, together with the treatments made up to 25 µl with SFDM. All the culture plates contained at least 12 control wells receiving SFDM only. After 24-h incubation with the test substances, the medium was replaced and the wells were then treated with 0.1 µmol/l GnRH (Fertagyl: Intervet UK Ltd, Cambridge, UK) in 50 µl of SFDM. In all dishes, eight wells previously exposed to SFDM received GnRH alone while four wells previously exposed to SFDM received 50 µl of SFDM instead of the 50 µl of GnRH challenge. These acted as controls for the magnitude of the GnRH response. Cultures were terminated after 4 h incubation by collecting the media, which was stored at 20°C for subsequent measurement of GnRH-induced LH as an index of GnSAF bioactivity. The QC follicular fluid was added to each bioassay at 1, 5 and 25 µl/well, in at least four wells/dose/separate culture, to act as a GnSAF quality control.
Hormone assays
Concentrations of LH in cell-conditioned media from rat anterior pituitary cell cultures were determined using a homologous time-resolved fluoro-immunoassay (DELFIA) in which rat LH was labelled with europium instead of 125I and the assays were performed in microtitre plates. In other respects, the assay closely followed our existing rat radioimmunoassay (Fowler et al., 1994). Sensitivity and intra-assay and inter-assay coefficient of variation (CV) values were: 0.2 ng LH/ml (NIDDK-rLH-RP3) using NIDDK-anti-rLH-S11 and 5.4 and 7.9% respectively. Activin-A was measured using a two-site ELISA previously described (Knight et al., 1996
; Muttukrishna et al., 1996
) in which follistatin does not interfere. This assay has a sensitivity of 50 ng recombinant human activin-A/L (gift from Genentech Inc., San Francisco, CA, USA) and mean intra- and inter-assay CVs of 5.0 and 9.1% respectively. The recombinant human activin-A is equipotent with the proposed candidate WHO 91/626 Reference Reagent for human activin-A. Inhibin-A concentrations were determined with a two-site ELISA previously described (Muttukrishna et al., 1994
, 1995
) with a sensitivity of 2 ng recombinant human inhibin-A/L (a gift from Dr M.Rose, NIBSC, Potters Bar, Herts, UK) and mean intra- and inter-assay CVs of 3.7 and 9.5% respectively. Inhibin-B was measured using a two-site ELISA previously described (Lockwood et al., 1996
; Muttukrishna et al., 1997
) with a sensitivity of 12 ng recombinant inhibin-B/L (gift from Genentech Inc.) and intra- and inter-assay CVs of 6.2 and 9.5% respectively.
Statistical analysis
The in-vitro pituitary cell responses are expressed as percentages of the relevant control gonadotrophin concentrations secreted from wells on the same culture dishes. These controls were either wells exposed to SFDM alone (basal secretion) or wells exposed to SFDM + 0.1 µmol/l GnRH. The differences between treatment groups and dose-responses were assessed using two-way analysis of variance (ANOVA) of the combined bioassay data from two separate bioassays. Differences between treatments and controls were tested by Dunnet's post hoc test and between treatments by the Bonferroni-Dunn post hoc test. Median effective doses (ED50) for GnSAF bioactivity were calculated from the dose-response curves by polynomial regression equations fitted separately for each dose-response curve. In this study, the ED50 is defined as the volume (µl) of QC follicular fluid/well dose required to produce 50% of its maximum suppression of GnRH-induced LH secretion in the relevant matching pairs of bioassays. To convert the ED50 values from an inverse relationship with bioactivity (the smaller the ED50 value the greater the GnSAF bioactivity) to positive values >1, which allows more direct comparison with other hormone titres, arbitrary units of GnSAF were calculated as follows: [(1/(ED50 for serum pool or fraction/ED50 QC hFF in matching cultures)]x10.
Relationships between variables were analysed by simple linear correlation with significance established using Fischer's Z statistic. The analyses were performed using the Statview 5 programme (Abacus Concepts Inc., Berkley, CA, USA). All results are presented as means ± SEM.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
|
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The relationship between follicle size and GnSAF bioactivity is qualitatively similar to that demonstrated by us for IVF-derived follicular fluid (Fowler et al., 1994). Direct comparison between the latter and the current study cannot, however, be made: firstly, because the bioassay used has evolved and become considerably more sensitive and secondly, due to the nature of bioassays, it would be necessary to run both sets of follicular fluid in the same assay to obtain a valid comparison. Although the trends are essentially similar, the difference in GnSAF bioactivity between follicles <11 mm and >21 mm from IVF cycles appeared to be in the order of 200-fold. The current study and data on inhibins and activins (Fowler et al., 1994
, 1995
; Magoffin and Jakimiuk, 1998; Lau et al., 1999
) demonstrate more modest changes in follicular fluid concentrations of these hormones in different sized follicles. It is likely, therefore, that our current findings of a 4-fold decrease in GnSAF bioactivity between 56 mm and 25 mm follicles from spontaneous cycles is more physiological than in the aforementioned IVF study (Fowler et al., 1994
).
There has always been a concern that inhibin may account for some or all GnSAF bioactivity (Culler, 1992). In the current study, the lack of relationship between GnSAF bioactivity and inhibin-A, inhibin-B or activin-A in follicular fluid from this large range of follicle sizes is clear evidence that these hormones do not account for observed GnSAF bioactivity. This is in agreement with earlier findings, including our investigation of GnSAF bioactivity in follicular fluid aspirated during spontaneous cycle IVF (Fowler et al., 1995
), studies utilizing inhibin antiserum (Byrne et al., 1995
) and the study by Kita et al. (Kita et al., 1994
) showing no relationship between inhibin and GnSAF in pig follicles of different sizes. Indeed, as can be seen in Figure 2
, inhibin-A appeared to increase with decreasing GnSAF bioactivity although this relationship was not linear due to the close clustering of the data at the lower end of the scale. The lack of a relationship between inhibin-B and GnSAF bioactivity in the different size follicles is more surprising. It is known that inhibin-B titres in the peripheral circulation are dependent upon the action of FSH: raising FSH increases inhibin-B titres in the peripheral circulation within 36 h (Burger et al., 1998
). In contrast, circulating inhibin-B concentrations fall sharply following GnRH antagonist administration (which reduces gonadotrophin secretion) during the follicular phase (Welt et al., 1999
). Similarly, GnSAF bioactivity is detectable in women within 8 h following FSH administration (Messinis et al., 1994
). The fact that follicular fluid concentrations of GnSAF and inhibin-B did not correlate therefore suggests differences in the regulation of GnSAF and inhibin-B production.
Circulating concentrations of GnSAF are probably a result of a variety of factors, including: (i) follicular fluid concentrations of GnSAF, (ii) numbers of follicles, (iii) sizes of the follicles, (iv) the volume:surface area ratios of the follicles, (v) permeability of the follicular basement membranes and (vi) degree of any active transport and diffusion of GnSAF out of the follicles. Unfortunately, very little is known about the dynamics of follicle:circulation transport. However, follicular fluid concentrations of some hormones correlate with circulating concentrations, as is the case with inhibin-B (Hall et al., 1999). Therefore, if our early pilot results showing peak GnSAF concentrations in the circulation during the early and mid-follicular phases (Byrne et al., 1993
; Martinez et al., 2000
) are physiological, then the follicular concentrations of GnSAF will be an important component in determining circulating GnSAF titres. Therefore, when the ovary contains a number of small healthy follicles, such as in the early to mid-follicular phase, circulating GnSAF will be maximal, but with the establishment of dominance and atresia of the subordinate follicles from the mid-follicular phase onwards, GnSAF titres will decline, reducing the `clamping' effect of GnSAF on pituitary responsiveness to GnRH.
In conclusion, we have demonstrated that GnSAF bioactivity in the follicular fluid during spontaneous cycles is inversely related to follicle size, but not to inhibin or activin concentrations. These findings are in agreement with previous studies using follicular fluid collected during IVF cycles, and support the concept of a physiological role for GnSAF in the regulation of LH secretion during the follicular phase. Studies to determine the site of GnSAF production and the mode of regulation of GnSAF secretion by FSH are ongoing.
![]() |
Acknowledgements |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
![]() |
Notes |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Byrne, B., Fowler, P.A., Messinis, I.E. and Templeton, A. (1993) Gonadotrophin surge-attenuating factor secretion varies during the follicular phase of the menstrual cycle of spontaneously cycling women. J. Endocrinol., 139, P53.
Byrne, B., Fowler, P.A., Fraser, M. et al. (1995) GnSAF bioactivity in serum from superovulated women is not blocked by inhibin antibody. Biol. Reprod., 52, 8895.[Abstract]
Culler, M.D. (1992) In vivo evidence that inhibin is a gonadotropin surge-inhibiting/attenuating factor. Endocrinology, 131, 15561558.[Abstract]
Danforth, D.R. and Cheng, C.Y. (1995) Purification of a candidate gonadotropin surge inhibiting factor from porcine follicular fluid. Endocrinology, 136, 16581665.[Abstract]
Fowler, P.A. and Templeton, A. (1996) The nature and function of putative gonadotropin surge-attenuating/inhibiting factor (GnSAF/IF). Endocr. Rev., 17, 103120.[ISI][Medline]
Fowler, P.A., Fraser, M., Cunningham, P. et al. (1994) Higher gonadotrophin surge-attenuating factor (GnSAF) bioactivity is found in small follicles from superovulated women. J. Endocrinol., 143, 3344.[Abstract]
Fowler, P.A., Fahy, U., Culler, M.D. et al. (1995) GnSAF bioactivity is present in follicular fluid from naturally cycling women. Hum. Reprod., 10, 6874.[Abstract]
Hall, J.E., Welt, C.K. and Cramer, D.W. (1999) Inhibin A and inhibin B reflect ovarian function in assisted reproduction but are less useful at predicting outcome. Hum. Reprod., 14, 409415.
Kita, M., Taii, S., Kataoka, N. et al. (1994) Changes of gonadotrophin surge inhibiting/attenuating factor activity in pig follicular fluid in relation to follicle size. J. Reprod. Fertil., 101, 5966.[Abstract]
Knight, P.G., Muttukrishna, S. and Groome, N.P. (1996) Development and application of a two-site enzyme immunoassay for the determination of `total' activin-a concentrations in serum and follicular fluid. J. Endocrinol., 148, 267279.[Abstract]
Koppenaal, D.W., Tijssen, A.M.I. and de Koning, J. (1992) The effect of gonadotrophin surge-inhibiting factor on the self-priming action of gonadotrophin-releasing hormone in female rats in vitro. J. Endocrinol., 134, 427436.[Abstract]
Lau, C.P., Ledger, W.L., Groome, N.P. et al. (1999) Dimeric inhibins and activin A in human follicular fluid and oocyte-cumulus culture medium. Hum. Reprod., 14, 23252530.
Lockwood, G.M., Muttukrishna, S., Groome, N.P. et al. (1996) Circulating inhibins and activin A during GnRH-analogue down-regulation and ovarian hyperstimulation with recombinant FSH for in-vitro fertilization-embryo transfer. Clin. Endocrinol., 45, 741748.[ISI][Medline]
Martinez, F., Knight, P.G., Groome, N.P. et al. (2000) Circulating gonadotrophin surge-attenuating factor (GnSAF), inhibin-A and inhibin-B concentrations are reduced in women with previous spontaneous luteinisation during IVF. J. Reprod. Fertil., 25, 253.
Magoffin, D.A. and Jakimiuk, A.J. (1997) Inhibin A, inhibin B and activin A in the follicular fluid of regularly cycling women. Hum. Reprod., 12, 17141719.[Abstract]
Messinis, I.E., Lolis, D., Zikopoulos, K. et al. (1994) Effect of an increase in FSH on the production of gonadotrophin surge-attenuating factor in women. J. Reprod. Fertil., 101, 689695.[Abstract]
Muttukrishna, S., Fowler, P.A., Groome, N. et al. (1994) Serum concentrations of dimeric inhibin during the spontaneous human menstrual cycle and after treatment with exogenous gonadotrophin. Hum. Reprod., 9, 16341642.[Abstract]
Muttukrishna, S., George, L., Fowler, P.A. et al. (1995) Measurement of serum concentrations of dimeric inhibin during human pregnancy. Clin. Endocrinol., 42, 391397.[ISI][Medline]
Muttukrishna, S., Fowler, P.A., George, L. et al. (1996) Changes in peripheral serum levels of total activin-A during the human menstrual cycle and pregnancy. J. Clin. Endocrinol. Metab., 81, 33283334.[Abstract]
Muttukrishna, S., Knight, P.G., Groome, N.P. et al. (1997) Activin A and inhibin A as possible endocrine markers for pre-eclampsia. Lancet, 349, 12851288.[ISI][Medline]
Pappa, A., Seferiadis, K., Fotsis, T. et al. (1999) Identification of a candidate gonadotrophin surge attenuating factor from human follicular fluid. Hum. Reprod., 14, 14491456.
Robertson, D.M., Cahir, N., Findlay, J.K. et al. (1997) The biological and immunological characterisation of inhibin A and B forms in human follicular fluid and plasma. J. Clin. Endocrinol. Metab., 82, 889896.
Tio, S., Koppenaal, D., Bardin, C.W. and Cheng, C.Y. (1994) Purification of gonadotropin surge-inhibiting factor from Sertoli cell-enriched culture medium. Biochem. Biophys. Res. Commun., 199, 12291236.[ISI][Medline]
Welt, C.K., Adams, J.M., Sluss, P.M. and Hall, J.E. (1999) Inhibin A and inhibin B responses to gondotropin withdrawal depends upon stage of follicle development. J. Clin. Endocrinol. Metab., 84, 21632169.
Submitted on November 24, 2000; accepted on March 12, 2001.